Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports

Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports

The management of patients with myelodysplastic syndrome (MDS) refractory to hypomethylating agents (HMAs) remains a challenge with few reliably effective treatments. Preclinical studies have shown that the inhibition of the nuclear export protein XPO1 causes nuclear accumulation of p53 and disrupti...

Full description

Bibliographic Details
Main Authors: Yunshuo Xiao, Kun Yang, Qiuying Huang, Changqing Wei, Manlv Wei, Zhili Geng, Hui Wu, Tianhong Zhou, Xialoin Yin, Yali Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Oncology
Subjects:
selinexor
venetoclax
hypomethylating agents
myelodysplastic syndrome
acute myeloid leukemia
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1477697/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1477697/full

Similar Items